RACE-CARS: Do Community and EMS Interventions Improve Survival in Cardiac Arrest?

A multi-faceted intervention strategy for treating adults with out-of-hospital cardiac arrest that involved enhanced community and EMS education and training did not result in a greater percentage of patients surviving to hospital discharge with a favorable neurologic outcome vs. usual care, based on findings from RACE-CARS presented at AHA 2026 and simultaneously published in NEJM.

DETECT-HF and BETTER CARE-HF Evaluate Novel HF Alert Systems

Two presentations at AHA 2026 simultaneously published in JACC: Heart Failure evaluated two novel technologies: a voice-based heart failure (HF) monitoring system, and an EHR-embedded mineralocorticoid receptor antagonists (MRA) prescription prompt.

STREAM, eZ-PAVE Add New Insights Into Statin Therapy Treatment

Discontinuing statin therapy in older adults with at least two chronic conditions but no known cardiovascular disease was noninferior to continuation with respect to major cardiovascular events or death from any cause at two years, according to findings from the STREAM trial presented at AHA 2026 and simultaneously published in NEJM.

Lp(a) HORIZON: Pelacarsen vs. Placebo in Patients With High Lp(a)

Pelacarsen did not result in a lower risk of major adverse cardiovascular events compared with placebo in patients with preexisting cardiovascular disease and high lipoprotein(a) (Lp(a)) over a median follow-up period of approximately five years, based on findings from the Lp(a) HORIZON trial presented at AHA 2026 and simultaneously published in NEJM.

ZEUS: Interleukin-6 Inhibition With Ziltivekimab For High-Risk Patients With ASCVD, CKD and Systemic Inflammation

Anti-inflammatory therapy targeting interleukin-6 (IL-1β) with ziltivekimab (a monoclonal antibody) did not lower risks of cardiovascular events compared with placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD) and systemic inflammation, based on findings from the ZEUS trial presented at AHA 2026 and simultaneously published in NEJM.